PHAT

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Florham Park, New Jersey. The company went public in October 2019 and focuses on developing and commercializing novel treatments for gastrointestinal diseases. Phathom's primary asset is <b>VOQUEZNA</b> (vonoprazan), a potassium-competitive acid blocker that represents a new class of acid-suppressing medications for treating stomach acid-related conditions. The company has successfully launched VOQUEZNA in the United States and is working to expand its commercial footprint while developing additional indications for the drug.